The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Abstract
PURPOSE: To assess antitumor response and time to progression (TTP) with docetaxel compared with doxorubicin in first-line treatment of advanced and/or metastatic soft tissue sarcoma. PATIENTS AND METHODS: Patients with measurable soft tissue sarcoma lesions and adequate bone marrow, liver, and renal function were entered onto the study. They were randomized to either docetaxel 100 mg/m 2 given as a 1-hour intravenous infusion every 3 weeks or doxorubicin 75 mg/m 2 given as a bolus injection every 3 weeks. A maximum of seven cycles of treatment were scheduled. The study was designed as a randomized phase III study evaluating TTP by log-rank model. There was a clause for premature closure of the trial if fewer than five responses were observed among the first 25 assessable patients in the docetaxel treatment arm. RESULTS: Eighty-six patients were entered onto the study; 85 were assessable for toxicity and 83 for response. The rate of severe granulocytopenia was not significantly different between the two arms. Nausea (P = .001), vomiting (P < .001), and stomatitis (P = .005) were more common with doxorubicin therapy, whereas neurotoxicity was more frequent with docetaxel treatment. The response rate to doxorubicin therapy was 30% (95% confidence interval, 17% to 46%), whereas no responses to docetaxel therapy were seen (P < .001). In view of this, the trial was closed prematurely and the phase III study part was not conducted. CONCLUSION: Docetaxel is inactive in soft tissue sarcomas and cannot be recommended for further use in treatment of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cited by
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., Rubenstein, E. B., et al. (2004) · Cancer · doi:10.1002/cncr.20162 · Cited by 1,417
Young, R. J., Brown, N. J., Reed, M. W., Hughes, D., & Woll, P. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70023-1 · Cited by 962
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
Dematteo, R. P., Heinrich, M. C., El-Rifai, W. M., & Demetri, G. (2002) · Human Pathology · doi:10.1053/hupa.2002.124122 · Cited by 637
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P., Baker, L. H., Blay, J. Y., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 538
Metadata
- Authors
- Verweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., & Judson, I. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-05-10
- Volume
- 18
- Issue
- 10
- Pages
- 2081-2086
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1882650898
- Cited by
- 171
- References
- 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. https://app.cochat.ai/papers/10.1200/jco.2000.18.10.2081
- The paper
- Verweij, J., Lee, S. M., Ruka, W., Buesa, J., Coleman, R., van Hoessel, R., Seynaeve, C., di Paola, E. D., van Glabbeke, M., Tonelli, D., & Judson, I. R. (2000). Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.10.2081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.